
Spero Therapeutics SPRO
$ 0.74
-9.76%
Spero Therapeutics EBITDA per Share | SPRO
Annual EBITDA per Share Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | -1.36 | 0.41 | -1.1 | -2.83 | -4.31 | -3.44 | -2.65 | -16 | - | -0.971 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.41 | -16 | -3.21 |
Quarterly EBITDA per Share Spero Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.72 | -0.17 | -0.13 | 204 | -0.14 | -0.04 | -0.27 | -129 | -0.34 | -0.35 | -0.26 | 507 | -0.03 | -0.24 | -0.27 | 6.95 | -0.32 | -0.78 | -0.92 | -57.1 | -0.7 | -0.62 | -0.65 | -11.1 | -0.86 | -0.88 | -1.16 | -1.36 | -0.94 | -0.76 | -0.32 | -0.62 | -0.62 | -0.69 | -0.75 | -1.5 | -28.9 | -29.9 | -22.8 | - | -24.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 507 | -129 | 9.93 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Eiger BioPharmaceuticals
EIGR
|
-48.4 | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
-3.3 | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
-0.14 | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
-1.91 | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
-13.5 | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
-6.89 | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
-0.87 | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
-0.97 | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
0.8 | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
-3.71 | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
-0.54 | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
-2.82 | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
-4.47 | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
-0.39 | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
-2.25 | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
-4.11 | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
-0.58 | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
-3.48 | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-5.01 K | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
-1.03 | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
-3.95 | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
3.32 | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
-0.22 | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
-0.73 | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
-5.81 | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
1.71 | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
10.1 | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
-7.18 | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
-0.69 | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
3.03 | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
-0.89 | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
-1.07 | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
1.12 | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
-2.25 | $ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-2.67 | $ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
0.39 | $ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
-2.21 | $ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
-3.34 | $ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
-2.7 | $ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
1.63 | $ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
-3.47 | $ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
-1.1 | $ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
-0.73 | $ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
-6.21 | $ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
-1.09 K | $ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-0.87 | $ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
0.05 | $ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-10.5 | $ 12.36 | -9.55 % | $ 799 M |